MG-D-1007

MG-D-1007 is an investigational drug candidate developed by Metagone Biotech, currently in early-stage clinical development for the treatment of Alzheimer's disease and Dry Eye syndrome. The drug functions as an inhibitor of nuclear factor kappa B (NF-kB), a transcription factor that plays a central role in regulating the immune response and inflammation. In Alzheimer's disease, MG-D-1007 is intended to mitigate neuroinflammation, which is a key driver of neuronal damage and cognitive decline. For Dry Eye, it aims to reduce ocular surface inflammation, thereby improving symptoms and tear film stability. The drug is estimated to be in Phase 1/2 clinical trials based on company pipeline data.